Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Shares closed at a period high on November 2. Q3 revenue grew 36%, adjusted EPS beat consensus, and positive Phase 3 Pasatru results provided a separate clinical catalyst.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠High Profitability ⢠Low Leverage ⢠Cash Flow REGN offers strong profitability, a robust balance sheet, and reasonable valuation, but investors should monitor weakening liquidity, cash conversion, and modest margin pressure.
Price Behavior
Key Price Behavior Insights: ⢠Lower highs ⢠Support tested ⢠Weak momentum Support Level: $774â$775 Resistance Level: $793â$810 REGN remains bearish after a ~5% decline over the last month, with support at $774â$775 offering bounce potential but a break lower signaling risk unless it reclaims $793â$810.
Sentiment & News
Key News Insights: ⢠Lead Plaintiff Deadline ⢠Securities Class Action ⢠Product Growth Pipeline Regeneron faces escalating securities litigation ahead of the lead-plaintiff deadline, offset by management's growth outlook for EYLEA HD, DUPIXENT, and pipeline catalysts.
AI Summary
REGN is now a concentrated execution trade: its strong balance sheet and valuation support upside only if DUPIXENT sustains growth and EYLEA HD offsets biosimilar erosion while upcoming pipeline catalysts rebuild credibility after the Fianlimab failure; investors should wait for evidence of improved cash conversion and clinical delivery before assuming the selloff is a buying opportunity.
Description
Regeneron Pharmaceuticals, Inc. researches, develops, manufactures and commercializes biologic medicines across ophthalmology, immunology, oncology, infectious disease and other therapeutic areas. Its marketed portfolio includes ophthalmic and immunologic treatments such as EYLEA and Dupixent, alongside oncology and infectious disease products, and a pipeline of candidates for cardiovascular, metabolic, rare and hematologic conditions. The company maintains multiple collaboration and licensing arrangements with large pharmaceutical partners and government agencies and is headquartered in Tarrytown, New York, having been incorporated in 1988.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Nov 3 | Nov 10 | REGN | Regeneron Pharmaceuticals, Inc. | Shares closed at a period high on November 2. Q3 revenue grew 36%, adjusted EPS beat consensus, and positive Phase 3 Pasatru results provided a separate clinical catalyst. | Active | +0.0% |